APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Campus-Vienna-Biocenter 5, Wien,wien 1030,austria
- Phone
- +43 1 86565 77
- ap****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- apeiron-biologics.com
- Keywords
- Oncology, Immunomodulation, Biologics, Respiratory.
- HQ
- Wien, Wien
Apeiron Biologics Ag Questions
Apeiron Biologics Ag's helpline number is +43 1 86565 77
Apeiron Biologics Ag's website is apeiron-biologics.com
Apeiron Biologics Ag's LinkedIn profile is https://at.linkedin.com/company/apeiron-biologics
Apeiron Biologics Ag has
5 employees.
View email and phone details for 5
employees at Apeiron Biologics Ag.
Apeiron Biologics Ag's industry is
Biotechnology Research
Apeiron Biologics Ag's top competitors are
Oncoone,
Ribbon Bio,
Invios Innovative Immuno-Oncology,
A:head Bio Ag,
Proxygen,
Hookipa Pharma Inc.,
Lexogen,
Myllia Biotechnology,
Biotech Austria,
Valanx Biotech.
Apeiron Biologics Ag's support email address is apeiron@apeiron-biologics.com
Apeiron Biologics Ag's categories are Biotechnology Research
Apeiron Biologics Ag's founding year is 2003
